AR025659A1 - Uso de una combinacion de un modificador de biorespuesta y un agente quimioterapeutico para la manufactura de un medicamento para potenciar quimioterapiay para tratar tumores solidos - Google Patents

Uso de una combinacion de un modificador de biorespuesta y un agente quimioterapeutico para la manufactura de un medicamento para potenciar quimioterapiay para tratar tumores solidos

Info

Publication number
AR025659A1
AR025659A1 ARP000104818A ARP000104818A AR025659A1 AR 025659 A1 AR025659 A1 AR 025659A1 AR P000104818 A ARP000104818 A AR P000104818A AR P000104818 A ARP000104818 A AR P000104818A AR 025659 A1 AR025659 A1 AR 025659A1
Authority
AR
Argentina
Prior art keywords
modifier
combination
chemotherapeutic agent
manufacture
biorespuest
Prior art date
Application number
ARP000104818A
Other languages
English (en)
Spanish (es)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR025659A1 publication Critical patent/AR025659A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP000104818A 1999-09-15 2000-09-14 Uso de una combinacion de un modificador de biorespuesta y un agente quimioterapeutico para la manufactura de un medicamento para potenciar quimioterapiay para tratar tumores solidos AR025659A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39605199A 1999-09-15 1999-09-15

Publications (1)

Publication Number Publication Date
AR025659A1 true AR025659A1 (es) 2002-12-11

Family

ID=23565645

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104818A AR025659A1 (es) 1999-09-15 2000-09-14 Uso de una combinacion de un modificador de biorespuesta y un agente quimioterapeutico para la manufactura de un medicamento para potenciar quimioterapiay para tratar tumores solidos

Country Status (8)

Country Link
EP (1) EP1214092A2 (de)
JP (1) JP2003509383A (de)
CN (1) CN1391484A (de)
AR (1) AR025659A1 (de)
AU (1) AU7373600A (de)
BR (1) BR0014001A (de)
CA (1) CA2381078A1 (de)
WO (1) WO2001019399A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2444867C (en) * 2001-05-16 2010-08-17 Novartis Ag Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
CN109601739B (zh) * 2019-01-17 2022-10-14 河南湾流生物科技有限公司 一种复合氨基酸饲料添加剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042098A1 (en) * 1998-02-24 1999-08-26 Dovetail Technologies Inc. Small molecules that increase the conversion of food to body weight gain
AU2592600A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia

Also Published As

Publication number Publication date
CN1391484A (zh) 2003-01-15
BR0014001A (pt) 2002-05-21
WO2001019399A3 (en) 2001-12-13
AU7373600A (en) 2001-04-17
EP1214092A2 (de) 2002-06-19
WO2001019399A2 (en) 2001-03-22
JP2003509383A (ja) 2003-03-11
CA2381078A1 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
BR0307975A (pt) Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR0009213A (pt) Processos e composições para tratamento de tumores sólidos
BR0107869A (pt) Composições farmacêuticas eletrogiradas
BR0115162A (pt) Tratamentos antitumorais eficazes
ES2156840T1 (es) Medicamento que contiene polisulfato de pentosano e implante para tratar la fibrosis.
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
AR042051A1 (es) Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer
ES2062155T3 (es) Composiciones para el tratamiento de neoplasia que contienen un agente antineoplasico y un agente protector reductor de efectos secundarios.
MX9305934A (es) Nuevo modificador de resistencia a drogas multiples.
AR041023A1 (es) Composiciones y metodos para tratar el cancer usando inmunoconjugados de anticuerpo para cd44 citotoxicos y agentes quimioterapeuticos
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
ES2149264T3 (es) Agente terapeutico para el tratamiento de melanomas.
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
CR7575A (es) Uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario
AR011133A1 (es) MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA.
KR960700063A (ko) 사람 종양 세포내에서의 테모졸로마이드의 강화방법(Potentiation of temozolomide in human tumour cells)
CA2245890A1 (en) Use of an extract of cimicifuga racemosa
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
ES2133289T3 (es) Aumento en los niveles de glutation con glutamina.
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
BR0110150A (pt) Método e composição para o tratamento de câncer por meio da administração de agentes quimioterápicos indutores da apoptose
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.